Cooperative Research Council for Mental Health, Melbourne, Victoria, 3052, Australia.
Australian E-Health Research Centre, CSIRO Health & Biosecurity, Level 5, 901/16 Royal Brisbane & Women's Hospital, Brisbane, Queensland, 4029, Australia.
Alzheimers Res Ther. 2020 Mar 31;12(1):36. doi: 10.1186/s13195-020-00595-5.
β-amyloid (Aβ) positron emission tomography (PET) imaging is currently the only Food and Drug Administration-approved method to support clinical diagnosis of Alzheimer's disease (AD). However, numerous research studies support the use of cerebrospinal fluid (CSF) biomarkers, as a cost-efficient, quick and equally valid method to define AD pathology.
Using automated Elecsys® assays (Roche Diagnostics) for Aβ (1-42) (Aβ42), Aβ (1-40) (Aβ40), total tau (tTau) and phosphorylated tau (181P) (pTau), we examined CSF samples from 202 participants of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing cohort, to demonstrate the concordance with pathological AD via PET imaging.
Ratios Aβ42/Aβ40, tTau/Aβ42 and pTau/Aβ42 had higher receiver operator characteristic-area under the curve (all 0.94), and greater concordance with Aβ-PET (overall percentage agreement ~ 90%), compared with individual biomarkers.
Strong concordance between CSF biomarkers and Aβ-PET status was observed overall, including for cognitively normal participants, further strengthening the association between these markers of AD neuropathological burden for both developmental research studies and for use in clinical trials.
β-淀粉样蛋白（Aβ）正电子发射断层扫描（PET）成像目前是唯一获得美国食品和药物管理局批准的支持阿尔茨海默病（AD）临床诊断的方法。然而，大量研究支持使用脑脊液（CSF）生物标志物作为一种成本效益高、快速且同样有效的方法来定义 AD 病理学。
我们使用自动化 Elecsys®检测（罗氏诊断）检测 Aβ（1-42）（Aβ42）、Aβ（1-40）（Aβ40）、总tau（tTau）和磷酸化 tau（181P）（pTau），检查了来自澳大利亚成像、生物标志物和生活方式（AIBL）老化队列研究的 202 名参与者的 CSF 样本，以通过 PET 成像证明与病理性 AD 的一致性。
Aβ42/Aβ40、tTau/Aβ42 和 pTau/Aβ42 比值的受试者工作特征曲线下面积（均为 0.94）较高，与 Aβ-PET 的一致性也较高（总体百分比一致性约为 90%），与个别生物标志物相比。
总体而言，CSF 生物标志物与 Aβ-PET 状态之间存在很强的一致性，包括认知正常的参与者，进一步加强了这些 AD 神经病理学负担标志物在发展研究和临床试验中的关联。
